Aggressive lipid-lowering initiation abates new cardiac events (ALLIANCE)—rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease

This report describes the design and methodologic features of the Aggressive Lipid Lowering Initiation Abates New Cardiac Events (ALLIANCE) study, a 4-year, population-based, open-label randomized trial. ALLIANCE will determine whether aggressive lipid-lowering therapy with atorvastatin will decreas...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 2000-07, Vol.86 (2), p.250-252
Main Authors: Isaacsohn, Jonathan L, Davidson, Michael H, Hunninghake, Donald, Singer, Robert, McLain, Richard, Black, Donald M
Format: Article
Language:English
Subjects:
Adult
Aged
Anticholesteremic Agents - therapeutic use
Atorvastatin
Biological and medical sciences
Cardiovascular disease
Cholesterol, LDL - blood
Coronary Disease - blood
Coronary Disease - drug therapy
Female
General and cellular metabolism. Vitamins
Health care
Heptanoic Acids - therapeutic use
Humans
Hypercholesterolemia - blood
Hypercholesterolemia - drug therapy
Lipids
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Pyrroles - therapeutic use
Randomized Controlled Trials as Topic
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This report describes the design and methodologic features of the Aggressive Lipid Lowering Initiation Abates New Cardiac Events (ALLIANCE) study, a 4-year, population-based, open-label randomized trial. ALLIANCE will determine whether aggressive lipid-lowering therapy with atorvastatin will decrease the time to first ischemic event compared with usual medical care in patients with established coronary artery disease.
ISSN:0002-9149
1879-1913
DOI:10.1016/S0002-9149(00)00872-9